Syros Pharmaceuticals Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
Gerald Quirk
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | less than a year |
| CEO ownership | n/a |
| Management average tenure | no data |
| Board average tenure | 11.8yrs |
Recent management updates
Recent updates
Syros Pharmaceuticals: Entering A Decisive Era With An Expected 2024 Phase 3 Readout
Jul 02Syros Pharmaceuticals: Rising Despite Dilution, A Must Look
Jan 14Syros Pharmaceuticals: A Major Vote Of Confidence From Insiders
Sep 20Syros gets FDA orphan drug designation for pancreatic cancer treatment SY-5609
Sep 13Syros Pharmaceuticals Q2 2022 Earnings Preview
Aug 08CEO
Gerald Quirk (56 yo)
less than a year
Tenure
US$1,460,192
Compensation
Mr. Gerald E. Quirk, J.D., Esq., is President and Chief Executive Officer of Syros Pharmaceuticals, Inc. since 2024. He served as Chief Legal Officer at Syros Pharmaceuticals, Inc. since October 2022 until...
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Scientific Founder & Member of Scientific Advisory Board | 11.8yrs | no data | no data | |
| Independent Chairman | 8yrs | US$110.40k | 0.060% $ 3.9k | |
| Member of Scientific Advisory Board | 11.8yrs | no data | no data | |
| Independent Director | 9.3yrs | US$84.78k | 0.060% $ 3.9k | |
| Member of Scientific Advisory Board | 11.8yrs | no data | no data | |
| Director | 11.8yrs | US$1.49m | 0.015% $ 972.2 | |
| Member of Scientific Advisory Board | 11.8yrs | no data | no data | |
| Member of Scientific Advisory Board | 11.8yrs | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | 11.8yrs | no data | no data | |
| Member of Scientific Advisory Board | 11.8yrs | no data | no data | |
| Member of Scientific Advisory Board | 11.8yrs | no data | no data |
11.8yrs
Average Tenure
66yo
Average Age
Experienced Board: SYRS's board of directors are seasoned and experienced ( 11.8 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/05 02:26 |
| End of Day Share Price | 2025/01/03 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Syros Pharmaceuticals, Inc. is covered by 8 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Leah Rush Cann | Brookline Capital Markets |
| Andrew Fein | H.C. Wainwright & Co. |
| Mark Breidenbach | Oppenheimer & Co. Inc. |